ARCHIVES

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

The Cancer Letter Wins Awards (12-page issue).

June 13, 2003

Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone

June 29, 2012

NCI Rethinks Cancer Center Grants

March 14, 2014

HHS Orders Gallo Forum Canceled; Meeting May Be Held After OSI report final – Calabresi

July 3, 1992

Brain tumor foundations form collaboration.

July 15, 2005

“Sloppy” Cancer Control Grant Applications Turned Down At Twice NIH Disapproval Rate

November 7, 1975